SIRT1, 2, and 3 levels were downregulated shown to be in the Ishikawa cancer cells following a high dose (5 μM) MHY2256 or salermide (50 μM) treatment (Figure 1D), suggesting that MHY2256 might target various SIRT proteins. Here, SIRT1 is linked to cancer.